"10.1371_journal.pmed.1001809","plos medicine","2015-03-31T00:00:00Z","Amanda Mocroft; Jens D Lundgren; Michael Ross; Matthew Law; Peter Reiss; Ole Kirk; Colette Smith; Deborah Wentworth; Jacqueline Neuhaus; Christoph A Fux; Olivier Moranne; Phillipe Morlat; Margaret A Johnson; Lene Ryom; D:A:D study group, the Royal Free Hospital Clinic Cohort, and the INSIGHT, SMART, and ESPRIT study groups","Department of Infection and Population Health, University College London, London, United Kingdom; Copenhagen HIV Programme, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Division of Nephrology, Mount Sinai School of Medicine, New York, New York, United States of America; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia; Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; University of Minnesota, Minneapolis, Minnesota, United States of America; Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; Nephrology Department, Public Health Department, Centre Hospitalier Universitaire de Nice, Nice, France; Universit√© de Bordeaux, INSERM U 897, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Department of HIV Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom","Conceived and designed the experiments: AM JDL OK LR. Performed the experiments: AM JDL OK LR. Analyzed the data: AM. Enrolled patients: ML PR OK CS DW JN CAF OM PM MAJ. Wrote the first draft of the manuscript: AM JDL LR. Wrote the paper: AM JDL MR ML PR OK CS DW JN CAF OM PM MAJ LR. Agree with manuscript results and conclusions: AM JDL MR ML PR OK CS DW JN CAF OM PM MAJ LR. All authors have read, and confirm that they meet, ICMJE criteria for authorship.","PM: honoraria or travel/meeting expenses from Bristol-Myers Squibb, Gilead, Janssen-Cilag, Merck Sharp & Dohme-Chibret and ViiV Healthcare in the past five years. ML received unrestricted grants to my institution from Boehringer Ingelhiem, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag, ViiV HealthCare. CS has received funds for preparation of Educational Materials from Janssen, Gilead, BMS, ViiV HealthCare, support for attendance at Ad board and support to attend HIV conference from Gilead, funding to conduct study from BMS. OM has received honoraria as a speaker from Abbott and Gilead Sciences, serves on the board of Roche, and had expenses paid by Roche and Baxter for travel, accommodations, and meetings. OK has received honoraria, consultancy, lecture fees, and travel grants from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Roche, and ViiV Healthcare, and has served/is serving on Advisory Boards for Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare. AM has received honoraria, consultancy, lecture fees, and travel grants from Gilead Sciences, Merck Sharp & Dohme, Boehringer Ingelheim, Pfizer and GSK.","2015","03","Amanda Mocroft","AM",15,TRUE,4,4,1,3,TRUE,TRUE,FALSE,0,NA,FALSE
